Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 7 Sept 2026Clinical review pending
!
Secondary glaucoma with pain, new vessels or recent surgery
A painful eye with reduced vision and raised pressure may reflect neovascular disease, inflammation, trauma or a postoperative mechanism, each requiring more than routine chronic glaucoma treatment.
Action: Arrange emergency ophthalmic assessment for acute visual loss, severe pain, iris or angle new vessels, or a symptomatic postoperative eye; communicate the associated retinal, inflammatory, drug or trauma history.
Synopsis
Identify the cause of secondary pressure elevation, distinguish open-angle obstruction from secondary closure, and coordinate pressure control with treatment of the underlying ocular disorder.
Secondary glaucoma means optic nerve injury associated with an identifiable ocular disease, treatment or injury; isolated secondary ocular hypertension does not yet establish glaucoma.
Inspect the cornea, iris, lens and angle as well as the optic nerve; pressure measurement alone cannot identify the cause.
Pigment dispersion and pseudoexfoliation can obstruct outflow while the angle remains open, whereas neovascular membranes or secondary displacement can close it.
Key red flags
A painful high-pressure eye with iris neovascularisation after retinal vein occlusion or proliferative diabetic retinopathy needs urgent retinal and glaucoma assessment to address both ischaemia and pressure.
Investigation priorities
01
Pressure, acuity and urgent anterior segment examinationFirst step
Assess current threat and identify a painful secondary emergency.
Management branches
Cause identificationClassify the secondary outflow problem
Raised pressure or optic neuropathy is accompanied by an unusual ocular history or anterior segment finding.
Assess immediate visual threat and examine the angle and anterior segment for pigment, exfoliation, inflammation, vessels and structural injury.
Review medicines, including non-ocular steroids, and obtain the timing of trauma, surgery, retinal events and previous pressure measurements.
Key medicines
Dorzolamide 20 mg/mL eye dropsUse one drop in each treated eye three times daily as monotherapy; when used as an adjunct to an ophthalmic beta-blocker, the selected product specifies one drop twice daily. Continue until a planned pressure review or a revised prescription.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.